Skip to main content

Advertisement

Table 6 Health care resource use associated with procedures

From: Health care resource use among patients with advanced non-small cell lung cancer: the PIvOTAL retrospective observational study

  Italy Spain Germany Australia Japan Korea Taiwan Brazil
1LT 2LT 1LT 2LT 1LT 2LT 1LT 2LT 1LT 2LT 1LT 2LT 1LT 2LT 1LT 2LT
N = 174 N = 101 N = 202 N = 96 N = 139 N = 64 N = 208 N = 128 N = 175 N = 105 N = 150 N = 96 N = 217 N = 155 N = 175 N = 91
No. imaging tests, n 155 85 186 72 133 53 191 115 160 97 142 91 192 117 149 72
 Mean (SD) 3.4 (2.6) 3.0 (3.1) 4.6 (3.4) 3.9 (3.3) 7.0 (4.9) 5.3 (3.4) 5.4 (5.0) 4.7 (4.3) 16.7 (12.7) 10.2 (7.8) 9.3 (8.7) 10.0 (8.9) 11.5 (13.4) 10.6 (14.8) 3.6 (3.7) 3.0 (2.4)
 Median (range) 3 (1–13) 2 (1–17) 4 (1–23) 3 (1–21) 6 (1–31) 5 (1–16) 4 (1–33) 3 (1–23) 14 (1–68) 8 (1–39) 7 (1–75) 8 (1–48) 8 (1–86) 5 (1–86) 3 (1–31) 2 (1–11)
Imaging test type, n (%)a
 Radiograph 42 (27) 16 (19) 77 (41) 25 (35) 93 (70) 30 (57) 112 (59) 55 (48) 147 (92) 87 (90) 99 (70) 68 (75) 123 (64) 87 (74) 16 (11) 7 (10)
 PET scan 45 (29) 12 (14) 39 (21) 5 (7) 41 (31) 5 (9) 56 (29) 7 (6) 14 (9) 4 (4) 99 (70) 22 (24) 42 (22) 1 (1) 43 (29) 6 (8)
 CT scan 146 (94) 78 (92) 173 (93) 65 (90) 127 (96) 48 (91) 170 (89) 109 (95) 145 (91) 88 (91) 131 (92) 90 (99) 180 (94) 86 (74) 136 (91) 69 (96)
 MRI 28 (18) 10 (12) 70 (38) 21 (29) 56 (42) 12 (23) 32 (17) 20 (17) 107 (67) 58 (60) 103 (73) 33 (36) 72 (38) 32 (27) 52 (35) 15 (21)
 Ultrasound 8 (5) 6 (7) 18 (10) 2 (3) 19 (14) 2 (4) 46 (24) 17 (15) 19 (12) 2 (2) 25 (18) 5 (6) 39 (20) 19 (16) 8 (5) 5 (7)
 Other 16 (10) 4 (5) 32 (17) 10 (14) 61 (46) 9 (17) 38 (20) 15 (13) 92 (58) 31 (32) 53 (37) 29 (32) 102 (53) 26 (22) 48 (32) 11 (15)
No. biopsy-related procedure 129 1 147 3 124 3 146 1 147 0 129 3 168 2 113 1
 Mean (SD) 1.0 (0.2) 1 (n/a) 1.1 (0.3) 1.0 (0) 1.2 (0.4) 1.0 (0) 1.1 (0.3) 1.0 (n/a) 1.1 (0.4) n/a 1.2 (0.4) 1.3 (0.6) 1.1 (0.2) 1.0 (0) 1.0 (0.2) n/a
 Median (range) 1 (1–2) 1 1 (1–3) 1 (1–1) 1 (1–4) 1 (1–1) 1 (1–3) 1 (1–1) 1 (1–5) n/a 1 (1–2) 1 (1–2) 1 (1–2) 1 (1–1) 1 (1–2) 1 (1–1)
No. biomarker tests 67 6 120 10 67 3 89 16 84 2 102 6 150 3 45 11
 Mean (SD) 1.2 (0.4) 1 (0) 1.5 (0.9) 1.0 (0) 2.4 (1.4) 1.7 (1.2) 1.5 (0.8) 1.7 (1.1) 1.1 (0.4) 1.0 (0) 2.2 (0.9) 1.7 (1.2) 1.0 (0) 1.0 (0) 1.1 (0.3) 1.2 (0.4)
 Median (range) 1 (1–2) 1 (1–1) 1 (1–6) 1 (1–1) 2 (1–8) 1 (1–3) 1 (1–3) 1 (1–5) 1 (1–2) 1 (1–1) 2 (1–4) 1 (1–4) 1 (1–1) 1 (1–1) 1 (1–2) 1 (1–2)
Test type, number
 ALK 17 4 30 1 34 2 16 8 14 1 48 2 0 0 7 4
 EGFR 64 2 110 8 62 1 85 10 81 1 96 5 150 3 42 8
 Other 2 0 18 1 47 2 29 7 0 0 80 2 0 0 0 1
  1. aIn Germany, the imaging test type was unknown or missing for two imaging tests during first-line and one imaging test during second-line therapy
  2. 1LT first-line therapy, 2LT second-line therapy, ALK anaplastic lymphoma kinase, CT computed tomography, EGFR epidermal growth factor receptor, LOS length of stay, MRI magnetic resonance imaging, n/a not applicable, No. number of, OP outpatient, PET positron emission tomography